Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study
PLOS One · 2025
DOI: 10.1371/journal.pone.0323935 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Masaki Nakamura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Kitasato University School of Medicine, Kitazato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Rifampin, Trimethoprim, Sulfamethoxazole Drug Combination, Staphylococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kitasato University School of Allied Health Sciences.
Abstract (Originalsprache)
Methicillin-resistant Staphylococcus aureus (MRSA) is highly drug-resistant. The current Japanese guidelines (2019 edition) for managing and treating MRSA infections mention alternative anti-MRSA agents, including sulfamethoxazole-trimethoprim (ST) and rifampicin (RFP). Both ST and RFP are oral drugs and are expected to be effective alternatives to anti-MRSA drugs in clinical cases where anti-MRSA drugs are not indicated. Although guidelines for treating MRSA infections describe the efficacy of ST-RFP combination therapy and although it is used in clinical practice, only a limited number of in vitro studies have demonstrated its efficacy in pharmacokinetic/pharmacodynamic models. This study aimed to investigate the efficacy of the combination therapy of ST-RFP against MRSA in some in vitro models, including a pharmacokinetic/pharmacodynamic model. The MRSA strains obtained were subjected to antibiotic susceptibility tests. A checkerboard assay for drug combination synergy of ST-RFP was performed. Furthermore, a chemostat model was used to validate the combination therapy of ST-RFP as an in vitro pharmacokinetic/pharmacodynamic model. Viable cell counts and antibiotic concentrations were measured. The checkerboard assay showed that the ST-RFP combination had an additive effect on all strains (the lowest fractional inhibitory concentration index ranged from 0.63 to 1.00). The in vitro chemostat model demonstrated the usefulness of the combination of ST-RFP against MRSA, especially in ST-resistant strains. Regrowth of MRSA was observed in RFP monotherapy but not in the ST-RFP combination therapy. This study demonstrated the potential effectiveness of the ST-RFP combination against ST-resistant MRSA, providing important foundational data that may support future clinical investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Kitasato University School of Medicine, Kitazato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan.
- Ōmura Satoshi Memorial Institute, Kitasato University, Shirokane, Minato-ku, Tokyo 108-8641, Japan.
- Laboratory of Clinical Pharmacokinetics, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, Shirokane, Minato-ku, Tokyo 108-8641, Japan.
ORCID-Profile: Masaki Nakamura
Förderung
- Kitasato University School of Allied Health Sciences
Zitieren
APA
Nakamura, M., Tomoda, Y., Kobayashi, M., Hanaki, H., & Kanoh, Y. (2025). Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study. PLOS One. https://doi.org/10.1371/journal.pone.0323935
Vancouver
Nakamura M, Tomoda Y, Kobayashi M, Hanaki H, Kanoh Y. Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study. PLOS One. 2025. doi:10.1371/journal.pone.0323935
BibTeX
@article{Nakamura2025,
author = {Nakamura, Masaki and Tomoda, Yoshinori and Kobayashi, Masahiro and Hanaki, Hideaki and Kanoh, Yuhsaku},
title = {Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0323935}
}
EUVIMED